We've Moved Forward

By Louis Garguilo, Chief Editor, Outsourced Pharma

We might have expected this CMO Leadership Awards issue to focus heavily on the year 3 CE (Covid Era). But what we’ve discovered is this: We’ve moved forward collectively as an industry, despite the COVID circumstances, to re-enter the broader historicism of the year 2022 regarding our drug development and manufacturing outsourcing strategies and tactics. Don’t get me wrong; we will cover the COVID challenge in this issue, for example, via articles such as, “A Better Path For CMO Relationships As The Pandemic Continues.” More so, though, what you’ll read in these pages is the importance of continuing to advance the knowledge, best practices, and strategies of outsourcing we’ve been covering now for nearly a decade in this issue.